Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly

References

• Heart disease and stroke statistics – 2010 update. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3018163. Accessed 2010 Nov 22.
   Google Scholar
• GopalABudoffMJCoronary calcium scanning in geriatric cardiologyAm J Geriatr Cardiol20071636937517975335
   PubMedGoogle Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• AkosahKOSchaperACogbillCPreventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines performJ Am Coll Cardiol2003411475147912742284
   PubMed Web of Science ®Google Scholar
• MichosEDNasirKBraunsteinJBFramingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic womenAtherosclerosis200618420120615907856
   PubMed Web of Science ®Google Scholar
• DeMazumderDHasanRKBlumenthalRSMichosEDJonesSShould statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidenceAm J Cardiol201010690590920816135
   PubMed Web of Science ®Google Scholar
• AlexanderKPNewbyLKCannonCPAcute coronary care in the elderly, Part I: Non-ST-segment-elevation acute coronary syndromes: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology, in collaboration with the Society of Geriatric CardiologyCirculation20071152549256917502590
   PubMed Web of Science ®Google Scholar
• KellerNMFeitFCoronary artery disease in the geriatric populationProg Cardiovasc Dis1996384074188604446
   PubMed Web of Science ®Google Scholar
• HanonOCoronary artery disease in patients 80 years and olderRev Prat200858156170 French.
   Google Scholar
• DavidsonMHMakiKCPearsonTAResults of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP Writing Group recommendationsAm J Cardiol20059655656316098311
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAfor the JUPITER study groupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med20083592195220718997196
   PubMed Web of Science ®Google Scholar
• KapurNKRosuvastatin: A highly potent statin for the prevention and management of coronary artery diseaseExpert Rev Cardiovasc Ther2007516117517338662
   PubMedGoogle Scholar
• YildirirAMuderrisogluHNon-lipid effects of statins: Emerging new indicationsCurr Vasc Pharmacol2004230931815320810
   PubMedGoogle Scholar
• JonesPHDavidsonMHSteinEASTELLAR Study GroupComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)Am J Cardiol20039215216012860216
   PubMed Web of Science ®Google Scholar
• SchusterHBarterPJStenderSEffective Reductions in Cholesterol Using Rosuvastatin Therapy I study groupEffects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I)Am Heart J200414770571315077101
   PubMed Web of Science ®Google Scholar
• BallantyneCMBertolamiMHernandez GarciaHRAchieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patient: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY II)Am Heart J2006151975.e1979.e116644314
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAReduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trialLancet20093731175118219329177
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDfor the Treating to New Targets (TNT) InvestigatorsIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHfor the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (PROVE-IT TIMI 22)Intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med20043501495150415007110
   PubMed Web of Science ®Google Scholar
• PedersonTRCaterNBFaergemanOComparison of atorvastatin 80 mg/day vs simvastatin 20–40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)Am J Cardiol201010635435920643245
   PubMed Web of Science ®Google Scholar
• TzengTBSchneckDWBirminghamBKPopulation pharmacokinetics of rosuvastatin: Implications of renal impairment, race, and dyslipidaemiaCurr Med Res Opin2008242575258518674408
   PubMed Web of Science ®Google Scholar
• Clofibrate and niacin in coronary heart diseaseJAMA19752313603811088963
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study GroupRandomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial InvestigatorsN Engl J Med1996335100110098801446
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med1998339134913579841303
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals a randomized placebo controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• SheperdJBlauwGJMurphyMBfor the PROSPER study groupPravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trialLancet20023601623163012457784
   PubMed Web of Science ®Google Scholar
• BrugtsJJYetginTHoeksSEThe benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomized controlled trialsBMJ2009338b237619567909
   PubMed Web of Science ®Google Scholar
• DeedwaniaPStonePHBairey MerzCNEffect of intensive vs moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE)Circulation200711670070717664372
   PubMed Web of Science ®Google Scholar
• GransboKMelanderOWallentinLCardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatmentJ Am Coll Cardiol2010551362136920338498
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIfor the West of Scotland Coronary Prevention Study Group (WOSCOPS)Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaN Engl J Med1995333130113077566020
   PubMed Web of Science ®Google Scholar
• NakamuraHArakawaKItakuraHfor the MEGA groupPrimary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomized controlled trialLancet20063681155116317011942
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of (AFCAPS/TexCAPS) Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA1998279161516229613910
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRfor the ASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): A multicenter randomized controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• GlynnRJDanielsonEFonsecaFAA randomized trial of rosuvastatin in the prevention of venous thromboembolismN Engl J Med20093601851186119329822
   PubMed Web of Science ®Google Scholar
• GlynnRJKoenigWNordestgaardBGSheperdJRidkerPMRosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low density lipoprotein cholesterol levels: Exploratory analysis of a randomized trialAnn Intern Med201015248849620404379
   PubMed Web of Science ®Google Scholar
• LewingtonSWhitlockGClarkeRProspective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deathsLancet20073701829183918061058
   PubMed Web of Science ®Google Scholar
• NarlaVBlahaMJBlumenthalRSMichosEDThe JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: Perspectives, outcomes, and consequencesVasc Health Risk Manag200951033104220057896
   PubMedGoogle Scholar
• BasslerDBrielMMontoriVMStopping randomized trials early for benefit and estimation of treatment effects: Systematic review and meta-regression analysisJAMA20103031180118720332404
   PubMed Web of Science ®Google Scholar
• RidkerPMGlynnRJThe JUPITER trial: Responding to the criticsAm J Cardiol20101061351135621029837
   PubMed Web of Science ®Google Scholar
• MichosEDBlumenthalRSPrevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the USJ Am Coll Cardiol20095393193519281922
   PubMed Web of Science ®Google Scholar
• FellströmBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Engl J Med20093601395140719332456
   PubMed Web of Science ®Google Scholar
• FoleyRNMurrayAMLiSChronic kidney disease and the risk of cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999J Am Soc Nephrol20051648949515590763
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVfor the CORONA GroupRosuvastatin in older patients with systolic heart failureN Engl J Med20073572248226117984166
   PubMed Web of Science ®Google Scholar
• McMurrayJJKjekshusJGullestadLfor the CORONA Study GroupEffects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysisCirculation20091202188219619917888
   PubMed Web of Science ®Google Scholar
• LorgellyPKBriggsAHWedelHfor the CORONA Study GroupAn economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trialEur J Heart Fail201012667420023047
   PubMed Web of Science ®Google Scholar
• LemaitreRNFurbergCDNewmanABTime trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health StudyArch Intern Med1998158176117689738605
   PubMed Web of Science ®Google Scholar
• WhincupPHEmbersonJRLennonLWalkerMPapacostaOThomsonALow prevalence of lipid lowering drug use in older men with established coronary heart diseaseHeart200288252912067936
   PubMed Web of Science ®Google Scholar
• KoDTMamdaniMAlterDALipid-lowering therapy with statins in high risk elderly patients: The treatment-risk paradoxJAMA20042911864187015100205
   PubMed Web of Science ®Google Scholar
• GnaviRMigliardiADemariaMPetrelliACaprioglioACostaGStatins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalitiesEur J Public Health20071749249617303583
   PubMed Web of Science ®Google Scholar
• NiskaRHanBStatins for secondary cardiovascular disease prevention for older primary care patientsJ Natl Med Assoc200910170571019634592
   PubMed Web of Science ®Google Scholar
• KrumholzHMMurilloJEChenJThrombolytic therapy for eligible elderly patients with acute myocardial infarctionJAMA1997277168316889169894
   PubMed Web of Science ®Google Scholar
• RochonPAAndersonGMTuJVUse of beta-blocker therapy in older patients after acute myocardial infarction in OntarioCMAJ19991611403140810906894
   PubMed Web of Science ®Google Scholar
• SattarNPreissDMurrayHMStatins and the risk of incident diabetes: A collaborative meta-analysis of randomized statin trialsLancet201037573574220167359
   PubMed Web of Science ®Google Scholar
• AthyrosVGTziomalosKKaragiannisAMikhailidisDPLipid-lowering agents and new onset diabetes mellitusExpert Opin Pharmacother2010111965197020486831
   PubMed Web of Science ®Google Scholar
• RobinsonJGBakrisGTornerJStoneNJWallaceRIs it time for a cardiovascular primary prevention trial in the elderlyStroke20073844145017194877
   PubMed Web of Science ®Google Scholar